JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brooks, D. P.
Right arrow Articles by Ruffolo, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brooks, D. P.
Right arrow Articles by Ruffolo, R. J.

Prevention and complete reversal of cyclosporine A-induced renal vasoconstriction and nephrotoxicity in the rat by fenoldopam

DP Brooks, DJ Drutz and RR Ruffolo

Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania.

The primary mechanism of cyclosporine A-induced nephrotoxicity involves renal vasoconstriction. In the present study, we have tested the effects of fenoldopam, a dopamine DA1, receptor agonist with renal vasodilator properties, on the changes in renal function induced by acute and subacute administration of cyclosporine A. In inactin- anesthetized rats, acute administration of cyclosporine A (100 mg/kg i.p.) significantly decreased paraaminohippuric acid (PAH) and inulin clearances. Fenoldopam, at a dose (10 micrograms/kg.min) which alone significantly increased PAH and inulin clearances, completely prevented the cyclosporine A-induced reductions in renal function. Similarly, subacute administration of cyclosporine A (20 mg/kg.day for 3 days) resulted in significant reductions in base-line PAH and inulin clearances which were normalized by administration of fenoldopam. These data indicate that administration of fenoldopam can both prevent and completely reverse cyclosporine A-induced renal vasoconstriction and nephrotoxicity.

Volume 254, Issue 2, pp. 375-379, 08/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 PERSPECT VASC SURG ENDOVASC THERHome page
H. J. Safi, T. T. T. Huynh, H. T. Hassoun, C. C. Miller III, and A. L. Estrera
Preventing Renal Failure in Thoracoabdominal Aortic Aneurysm Repair
Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2004; 16(1): 3 - 11.
[Abstract] [PDF]

Home page
 NEJMHome page
M. B. Murphy, C. Murray, and G. D. Shorten
Fenoldopam -- A Selective Peripheral Dopamine-Receptor Agonist for the Treatment of Severe Hypertension
N. Engl. J. Med., November 22, 2001; 345(21): 1548 - 1557.
[Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1990 by the American Society for Pharmacology and Experimental Therapeutics.